Patents by Inventor Kenneth Dobie

Kenneth Dobie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense modulation of superoxide dismutase 1, soluble expression
    Publication number: 20040091919
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Application
    Filed: August 4, 2003
    Publication date: May 13, 2004
    Inventors: C. Frank Bennett, Kenneth Dobie
  • Antisense modulation of MyD88 expression
    Publication number: 20040038926
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MyD88. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MyD88. Methods of using these compounds for modulation of MyD88 expression and for treatment of diseases associated with expression of MyD88 are provided.
    Type: Application
    Filed: September 26, 2003
    Publication date: February 26, 2004
    Inventors: James Karras, Kenneth Dobie
  • Antisense modulation of MyD88 expression
    Publication number: 20030186903
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MyD88. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MyD88. Methods of using these compounds for modulation of MyD88 expression and for treatment of diseases associated with expression of MyD88 are provided.
    Type: Application
    Filed: November 23, 2001
    Publication date: October 2, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: James Karras, Kenneth Dobie
  • Antisense modulation of B-cell associated protein expression
    Publication number: 20030144224
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of B-cell associated protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding B-cell associated protein. Methods of using these compounds for modulation of B-cell associated protein expression and for treatment of diseases associated with expression of B-cell associated protein are provided.
    Type: Application
    Filed: December 13, 2001
    Publication date: July 31, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Kenneth Dobie
  • Antisense modulation of vitamin D nuclear receptor expression
    Publication number: 20030125271
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of vitamin D nuclear receptor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding vitamin D nuclear receptor. Methods are provided for using these compounds for modulation of vitamin D nuclear receptor expression, including examples of modulation of specific variants of vitamin D nuclear receptor relative to other variants. Methods for treatment of diseases associated with expression of vitamin D nuclear receptor are provided.
    Type: Application
    Filed: November 14, 2001
    Publication date: July 3, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brenda F. Baker, Kenneth Dobie, Mark P. Roach
  • Antisense modulation of thyroid hormone receptor interactor 6 expression
    Publication number: 20030125276
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of thyroid hormone receptor interactor 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding thyroid hormone receptor interactor 6. Methods of using these compounds for modulation of thyroid hormone receptor interactor 6 expression and for treatment of diseases associated with expression of thyroid hormone receptor interactor 6 are provided.
    Type: Application
    Filed: November 8, 2001
    Publication date: July 3, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Kenneth Dobie
  • Antisense modulation of activating transcription factor 3 expression
    Publication number: 20030125277
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of activating transcription factor 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding activating transcription factor 3. Methods of using these compounds for modulation of activating transcription factor 3 expression and for treatment of diseases associated with expression of activating transcription factor 3 are provided.
    Type: Application
    Filed: November 8, 2001
    Publication date: July 3, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brenda F. Baker, Kenneth Dobie
  • Antisense modulation of CD81 expression
    Publication number: 20030113914
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CD81. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD81. Methods of using these compounds for modulation of CD81 expression and for treatment of diseases associated with expression of CD81 are provided.
    Type: Application
    Filed: December 10, 2001
    Publication date: June 19, 2003
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Mark J. Graham, Kenneth Dobie